DiaMedica Therapeutics Inc. (DMAC)
NASDAQ: DMAC · Real-Time Price · USD
6.39
-0.36 (-5.33%)
Aug 28, 2026, 4:00 PM EDT - Market closed
DiaMedica Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
35
Market Cap
344.59M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Agenus | 132.69M |
| Sutro Biopharma | 45.70M |
| Foghorn Therapeutics | 36.74M |
| Zentalis Pharmaceuticals | 26.87M |
| Abeona Therapeutics | 25.52M |
| Upstream Bio | 3.16M |
| YD Bio | 510.36K |
| Palisade Bio | 500.00K |
DMAC News
- 19 days ago - DiaMedica Therapeutics Earnings Call Transcript: Q2 2026 - Transcripts
- 19 days ago - DiaMedica Therapeutics Quarterly report: Q2 2026 - Filings
- 19 days ago - DiaMedica Therapeutics Earnings release: Q2 2026 - Filings
- 20 days ago - DiaMedica Therapeutics reports Q2 EPS (19c), consensus (20c) - TheFly
- 20 days ago - DiaMedica Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights - Business Wire
- 26 days ago - DiaMedica Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Business Update August 11, 2026 - Business Wire
- 6 weeks ago - DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 2 months ago - DiaMedica Therapeutics announces dosing of first two patients in DM199 study - TheFly